{"Symbol": "MDCO", "AssetType": "Common Stock", "Name": "The Medicines Company", "Description": "The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "8 Sylvan Way, Parsippany, NJ, United States, 07054", "FullTimeEmployees": "62", "FiscalYearEnd": "December", "LatestQuarter": "0000-00-00", "MarketCapitalization": "6786328576", "EBITDA": "-159328992", "PERatio": "None", "PEGRatio": "-0.05", "BookValue": "0.482", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-2.961", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "-517000", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "86.67", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "109.7508", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "84.9", "200DayMovingAverage": "66.2244", "SharesOutstanding": "0", "SharesFloat": "0", "SharesShort": "23046674", "SharesShortPriorMonth": "22586301", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}